NASDAQ:TCDA - Nasdaq - US89610F1012 - Common Stock - Currency: USD
0.108
-0.01 (-10%)
The current stock price of TCDA is 0.108 USD. In the past month the price decreased by -34.62%. In the past year, price decreased by -98.91%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Tricida, Inc. is a pharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 57 full-time employees. The company went IPO on 2018-06-28. TRC101, is a non-absorbed, orally administered polymer designed to treat metabolic acidosis by binding and removing acid from the gastrointestinal (GI), tract. Its Veverimer, is a low-swelling, spherical polymer bead that is approximately 100 micrometers in diameter, which is a single, molecular weight, crosslinked polyamine molecule. The company is conducting renal outcomes clinical trial, VALOR-CKD (TRCA-303), to determine if veverimer slows CKD progression in patients with metabolic acidosis associated with CKD. The firm's VALOR-CKD trial is a randomized, double-blind, placebo-controlled, time-to-event trial.
TRICIDA INC
7000 Shoreline Court, Suite 201
South San Francisco CALIFORNIA 94080 US
CEO: Gerrit Klaerner
Employees: 57
Company Website: https://www.tricida.com/
Phone: 14154297800.0
The current stock price of TCDA is 0.108 USD. The price decreased by -10% in the last trading session.
The exchange symbol of TRICIDA INC is TCDA and it is listed on the Nasdaq exchange.
TCDA stock is listed on the Nasdaq exchange.
8 analysts have analysed TCDA and the average price target is 19.72 USD. This implies a price increase of 18159.26% is expected in the next year compared to the current price of 0.108. Check the TRICIDA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
TRICIDA INC (TCDA) has a market capitalization of 6.02M USD. This makes TCDA a Nano Cap stock.
TRICIDA INC (TCDA) currently has 57 employees.
TRICIDA INC (TCDA) has a resistance level at 0.16. Check the full technical report for a detailed analysis of TCDA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
TCDA does not pay a dividend.
TRICIDA INC (TCDA) will report earnings on 2023-03-27.
TRICIDA INC (TCDA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.36).
ChartMill assigns a fundamental rating of 2 / 10 to TCDA. Both the profitability and financial health of TCDA have multiple concerns.
Over the last trailing twelve months TCDA reported a non-GAAP Earnings per Share(EPS) of -2.36. The EPS increased by 32.38% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 45% to TCDA. The Buy consensus is the average rating of analysts ratings from 8 analysts.